Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes drugs in areas of unmet medical need such as human immunodeficiency virus (HIV) in the United States, Europe and internationally.
Revenue TTM 27.3B
Net Income TTM 6.2B
EBITDA TTM 12.5B
Debt/EBITDA TTM 2.5x
EBITDA Margin 45.9%
Net Margin 22.8%
Revenue TTM 27.3B
Net Income TTM 6.2B
EBITDA TTM 12.5B
Debt/EBITDA TTM 2.5x
EBITDA Margin 45.9%
Net Margin 22.8%
Zlecenie zamknięto ręcznie:
20 Sep